IQnovate

Last updated

IQnovate
Company typePublic
IndustryHealthcare Services & Facilities
Founded2011
Headquarters Sydney, Australia
Key people
George Syrmalis, CEO
ProductsLife Sciences Tools and Services
Revenue$1.2 million
Number of employees
10
Website IQnovate

IQnovate is an Australian life sciences organization that provides intellectual property asset management services and scientific advice to the biopharmaceutical industry. [1] [2] [3] The company is best known for providing services to government organizations and some of the world's largest biopharmaceutical organizations. [1] [3] IQnovate is listed on the National Stock Exchange of Australia under the ticker symbol IQN and on the OTC in New York under the symbol IQNDY. [1] [4]

Contents

IQnovate is headquartered in Sydney, Australia, and George Syrmalis is the company's current CEO. [1] [4]

History

George Syrmalis created the company to provide pharmaceutical, biotechnology, medical device companies, financial institutions and academic and government organizations with advanced asset management and scientific advisory services. [4] [5] At the time of its founding, IQnovate was the only company in Australia providing such services. [4]

IQnovate has been listed on Australian Securities Exchange since December 2011. [1] [5] At its IPO, the company had a market capitalization of $9.74 million. [1] [4]

Services

IQnovate's primary services include intellectual property asset management and consultation on scientific matters to members of the biopharmaceutical industry. [1] [6] The company also provides advisory services to financial institutions regarding investment strategies in the biotech sector. [6] [7] The company's staff consists of field-based medical science liaisons, specialty medical managers, medical communications, regulatory managers and pricing reimbursement experts. [1] [2] [3] [6]

IQnovate helps biopharmaceutical firms and other large organizations improve operational efficiency and regulatory compliance, hedge the risks associated with drug development and decrease development costs and time to market for new drugs. [6] [7] [8] The company engages in all aspects of the drug life cycle, and it provides services on all relevant issues in the biopharmaceutical sector, including disease management, product launches, and medical practice guidelines. [5] [7]

Related Research Articles

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development presently known as Fortrea is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is spin-off from Labcorp, which employs more than 70,000 people worldwide.

Pharming, a portmanteau of farming and pharmaceutical, refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming, or biopharming.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

In the life sciences, a contract research organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. A CRO may provide such services as biopharmaceutical development, biological assay development, commercialization, clinical development, clinical trials management, pharmacovigilance, outcomes research, and real world evidence.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. The company publishes the annual Parexel R&D Statistical Sourcebook and operates the Parexel-Academy.

IQVIA, formerly Quintiles and IMS Health, Inc., is an American Fortune 500 and S&P 500 multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of US$49 billion as of August 2021. As of 2023, IQVIA was reported to be one of the world's largest contract research organizations (CRO).

<span class="mw-page-title-main">Healthcare in Iran</span>

For health issues in Iran see Health in Iran.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

China has seen double-digit growth in its biotechnology industry and has gone from being one of the slowest to one of the fastest nations in the adoption of new biotechnologies. The biotech sector is seen in China and internationally as a core area of national scientific and economic development. The main national biotech body in the country is the China National Center for Biotechnology Development. The CNCBD is an organization established on November 3, 1983, under the Ministry of Science and Technology with the approval of the State Council. CNCBD is the sole national center to coordinate and implement the national S&T program in Biotechnology and Health.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Actelion</span> Swiss biopharmaceutical company

Actelion Pharmaceuticals Ltd. is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

Spotlight Innovation Inc. [STATUS CLOSED] was an American pharmaceutical holding company. The company maintained two subsidiaries: Caretta Therapeutics, Inc. and Celtic Biotech Iowa, Inc. Spotlight Innovation Inc. is based in Urbandale, Iowa and was publicly traded on the OTCQB marketplace under the stock ticker symbol, STLT.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

<span class="mw-page-title-main">Biotechnology Innovation Organization</span> Biotechnology advocacy association

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.

References

  1. 1 2 3 4 5 6 7 8 "IQnovate Ltd". OTC Markets. Retrieved 10 May 2013.
  2. 1 2 "Innovation and strategies for pharmas, biotechs and the R&D community: IQnovate". BioPharma Australasia Conference. Retrieved 10 May 2013.
  3. 1 2 3 "Profile: IQnovate Ltd (IQNDY.PK)". Reuters. Archived from the original on 5 March 2016. Retrieved 10 May 2013.
  4. 1 2 3 4 5 Bushell-Embling, Dylan. "IQnovate signs first deal since NSX listing". Life Scientist. Retrieved 10 May 2013.
  5. 1 2 3 "IQnovate Ltd". Inside View. Archived from the original on 29 June 2013. Retrieved 10 May 2013.
  6. 1 2 3 4 "Who Are We?". IQnovate. Archived from the original on 30 May 2013. Retrieved 10 May 2013.
  7. 1 2 3 "What We Do". IQnovate. Archived from the original on 3 June 2013. Retrieved 10 May 2013.
  8. ↑ "IQnovate Limited". CROAsia.net. Retrieved 10 May 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.